“And then in 2026, there's a slew of readouts for new molecular.”

In context

“ganization, and this is in the top quartile ninetieth percentile, actually. You look across the industry from a KMR data perspective. Certainly, the three setbacks that you talked about are very notable that we've taken into account from an R&D perspective. We learned from these. But what it does is now we have to look forward as the vision has already been created, looking forward to 10 plus new molecular entities that we want to bring forward by the end of the decade. And 30 plus new indications that we have planned for by the end of the decade. And they will start reading out now, and they we just started early. Yes. But a small opportunity would be in myelofibrosis, that will read out later this year. There is, of course, ADAPT, which is very eagerly awaited. By everyone just like us. And then in 2026, there's a slew of readouts for new molecular. So we are well planned for that one and looking forward to just growing the portfolio from there on. Chuck Triano: Right. Thanks, Samit. Let's move to our next question, please. Operator: The next question will come from Luisa Hector with Berenberg. Please go ahead. Luisa Hector: Thank you. Maybe just another question on Cobenfi. Just wondering how the readout from ARISE impacts your levels of confidence in Alzheimer's psychosis readout and perhaps any additional trials that you may be planning? Thank you. Christopher Boerner: Thanks, Luisa. I'll ask Samit to take that. Samit Hirawat: Yes. Thanks, Luisa, for the question. ARISE data has no impact. As we think about Alzheimer's disease psychosis. There are a few reasons for that. One, obviously the disease is very different. Two, Alzheimer”